Summary & Overview
HCPCS J9309: Polatuzumab Vedotin Injection, 1 mg
HCPCS Level II code J9309 designates polatuzumab vedotin-piiq billed per 1 mg and is used for administration of this injectable oncology therapy. This code matters nationally as polatuzumab vedotin is an advanced targeted agent for certain hematologic malignancies; accurate coding affects clinical documentation, reimbursement, and access to therapy across care settings. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J9309 represents, typical sites of service, and the clinical context for billing an injectable oncology agent. The publication summarizes payer coverage considerations and common billing modifiers used with this HCPCS code. It also provides benchmarking guidance for service lines that bill oncology injections, highlights relevant policy updates affecting HCPCS drug billing, and outlines administrative details clinics and hospitals commonly track when managing high-cost infused therapies. Data not available in the input is noted where appropriate.
Billing Code Overview
HCPCS Level II code J9309 represents the drug product polatuzumab vedotin-piiq, billed per 1 mg of the drug. This code is used for administration of the medication itself; the service type is injectable chemotherapy or targeted oncology therapy. The typical site of service for claims using J9309 is hospital outpatient departments, physician offices, or infusion centers where intravenous or injectable cancer therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) presents to an outpatient infusion center for systemic therapy. The oncology team prescribes polatuzumab vedotin-piiq given as part of a combination regimen. The patient arrives for pre-treatment assessment including vital signs, review of recent laboratory values (complete blood count with differential, comprehensive metabolic panel), and verification of venous access. After nursing verification of orders, the pharmacy compounds J9309 dosed per milligram and labels the syringe/vial. The infusion nurse performs time-out, confirms the medication, dose and patient identity, and administers the drug intravenously via peripheral IV or implanted port using standard infusion protocols and monitoring for infusion reactions. Post-infusion, the patient is observed for immediate adverse events, with documentation of drug name, amount administered (in milligrams), lot number, and any modifier or infusion-related events recorded on the claim. Typical site of service is an outpatient hospital infusion center or physician office infusion suite. The service type is an infusion/injection of an oncology biologic agent billed as a HCPCS Level II drug code per milligram (J9309).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any extent |